SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : LXR Biotech.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BRAVEHEART who wrote (135)1/7/1999 9:23:00 AM
From: BRAVEHEART  Read Replies (1) of 154
 
Hi Gang,

Here is some background on LXR. This certainly does not cover the R&D end and the potential it includes. Today's announcement is suggestive of that potential. In particular the following statement relative to one of LXR's programs.

"''SARPs regulate fundamental processes in the life/death cycle of cells and thereby have great potential as therapeutics,'' commented Paul J. Hastings, President and CEO of LXR. ''We are pleased that a company of the stature of Rhone-Poulenc Rorer has recognized the potential of SARPs. This collaboration is one of several that LXR plans to establish for the development of SARP technology for a number of diseases,'' added Mr. Hastings."

Message 7141454

BEST WISHES
LONE WOLF
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News